Henan Heluo Tailong Pharmaceutical Co., Ltd. announced that it expects to receive CNY 319.3 million in funding from Henan Taloph Pharmaceutical Stock Co.,Ltd
January 24, 2019
Share
Henan Heluo Tailong Pharmaceutical Co., Ltd. announced that it will receive CNY 319.3 million in its equity round of funding on January 25, 2019. The transaction will include participation from existing investor Henan Taloph Pharmaceutical Stock Co.,Ltd (SHSE:600222). The transaction has been approved at the 17th meeting of the 7th directorate of the investor and it does not need to be approved at the shareholders meeting. On closing of the transaction, company's registered capital will increase from CNY 50 million to CNY 369.3 million.
Henan Taloph Pharmaceutical Stock Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company operates four segments. Pharmaceutical Manufacturing segment is mainly engaged in pharmaceutical preparations and Chinese herbal medicine slices business. Its products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, Xiaoer Qingre Zhike oral liquid, Xiaoer Tuire oral liquid, Danshen oral liquid, Shengmaiyin, Fufang Yimu oral liquid, and various Chinese herbal medicine slices. Pharmaceutical and Medicinal Materials Circulation segment is mainly engaged in fresh processing business and traceable medicinal materials trading. Pharmaceutical Research and Development Services segment mainly provides technical services such as preclinical pharmaceutical research, clinical contract research organization (CRO) research, and registration application. Other segment is mainly engaged in investment business.
Henan Heluo Tailong Pharmaceutical Co., Ltd. announced that it expects to receive CNY 319.3 million in funding from Henan Taloph Pharmaceutical Stock Co.,Ltd
HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD 
